Risk of tuberculosis in a Chinese registry of rheumatoid arthritis and ankylosing spondylitis for tumour necrosis factor-α antagonists

APLAR Journal of Rheumatology

Volumn 9, Issue 2, 2006, Pages 170-174

  Huang, Feng ^a   Wang, Lisha ^a   Zhang, Jianglin ^a   Deng, Xiaohu ^a   Guo, Junhua ^a   Zhang, Yamei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Ankylosing spondylitis; Rheumatoid arthritis; Tuberculosis infection; Tumour necrosis factor antagonist

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ANTERIOR POSTERIOR AXIS; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE REGISTRY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG SAFETY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LUNG CALCIFICATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOUS LYMPHADENITIS;

EID: 33745934626     PISSN: 02190494     EISSN: 14798077     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2006.00193.x     Document Type: Article

References (14)

1. Ehlers S (2003) Role of tumour necrosis factor (TNF) in host defence against tuberculosis: Implications for immunotherapies targeting TNF. Ann Rheum Dis 62, ii37-42.
2. Maini R, St Clair EW, Breedveld F, et al. (1999) Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 354, 1932-9.
3. Khanna D, McMahon M, Furst DE (2004) Safety of tumour necrosis factor antagonists. Drug Saf 27, 307-24.
4. Heiberg MS, Nordvag BY, Mikkelsen K, et al. (2005) The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: A six-month, longitudinal, observational, multicenter study. Arthritis Rheum 52, 2506-12.
5. National Technic Steering Group of the Epidemiological Sampling for Tuberculosis. (2002) Report on fourth national epidemiological sampling suvey of tuberculosis. Chin J Tuberculosis Prevention 24, 65£-108.
6. Antoni C, Braun J (2002) Side effects of anti-TNF therapy: Current knowledge. Clin Exp Rheumatol 20, S152-7.
7. Askling J, Fored CM, Brandt L, et al. (2005 July) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52, 1986-92.
8. Carmona L, Hernandez-Garcia C, Vadillo C, et al. (2003) Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30, 1436-9.
9. Gomez-Reino JJ, Carmona L, Valverde VR, et al. (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 48, 2122-7.
10. Wolfe F, Michaud K, Anderson J, et al. (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50, 372-9.
11. Vlachaki E, Psathakis K, Tsintiris K, et al. (2005 May) Delayed response to anti-tuberculosis treatment in a patient on infliximab. Respir Med 99, 648-52.
12. Huang F, Chen XM, Liu CG, et al. (1991) The determination of NK cell activity in ankylosing spondylitis. Chin J Immunol 7, 93.
13. Huang F, Chen XM, Liu CG, et al. (1991) Peripheral blood lymphocyte assay in ankylosing spondylitis and rheumatoid arthritis. Chin J Exp Clin Immunol 3, 32.
14. Huang F, Chen XM, Liu CG, et al. (1991) Interleukin-2 and its receptor abnormalities in ankylosing spondylitis and rheumatoid arthritis. Chin J Immunol 7, 172.